Cargando…

MFS multidrug transporters in pathogenic fungi: do they have real clinical impact?

Infections caused by opportunistic fungal pathogens have reached concerning numbers due to the increase of the immunocrompromised human population and to the development of antifungal resistance. This resistance is often attributed to the action of multidrug efflux pumps, belonging to the ATP-bindin...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Catarina, Dias, Paulo J., Sá-Correia, Isabel, Teixeira, Miguel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035561/
https://www.ncbi.nlm.nih.gov/pubmed/24904431
http://dx.doi.org/10.3389/fphys.2014.00197
_version_ 1782318063061827584
author Costa, Catarina
Dias, Paulo J.
Sá-Correia, Isabel
Teixeira, Miguel C.
author_facet Costa, Catarina
Dias, Paulo J.
Sá-Correia, Isabel
Teixeira, Miguel C.
author_sort Costa, Catarina
collection PubMed
description Infections caused by opportunistic fungal pathogens have reached concerning numbers due to the increase of the immunocrompromised human population and to the development of antifungal resistance. This resistance is often attributed to the action of multidrug efflux pumps, belonging to the ATP-binding cassette (ABC) superfamily and the major facilitator superfamily (MFS). Although many studies have focused on the role of ABC multidrug efflux transporters, little is still known on the part played by the Drug:H(+) Antiporter (DHA) family of the MFS in this context. This review summarizes current knowledge on the role in antifungal drug resistance, mode of action and phylogenetic relations of DHA transporters, from the model yeast S. cerevisiae to pathogenic yeasts and filamentous fungi. Through the compilation of the predicted DHA transporters in the medically relevant Candida albicans, C. glabrata, C. parapsilosis, C. lusitaniae, C. tropicalis, C. guilliermondii, Cryptococcus neoformans, and Aspergillus fumigatus species, the fact that only 5% of the DHA transporters from these organisms have been characterized so far is evidenced. The role of these transporters in antifungal drug resistance and in pathogen-host interaction is described and their clinical relevance discussed. Given the knowledge gathered for these few DHA transporters, the need to carry out a systematic characterization of the DHA multidrug efflux pumps in fungal pathogens, with emphasis on their clinical relevance, is highlighted.
format Online
Article
Text
id pubmed-4035561
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-40355612014-06-05 MFS multidrug transporters in pathogenic fungi: do they have real clinical impact? Costa, Catarina Dias, Paulo J. Sá-Correia, Isabel Teixeira, Miguel C. Front Physiol Physiology Infections caused by opportunistic fungal pathogens have reached concerning numbers due to the increase of the immunocrompromised human population and to the development of antifungal resistance. This resistance is often attributed to the action of multidrug efflux pumps, belonging to the ATP-binding cassette (ABC) superfamily and the major facilitator superfamily (MFS). Although many studies have focused on the role of ABC multidrug efflux transporters, little is still known on the part played by the Drug:H(+) Antiporter (DHA) family of the MFS in this context. This review summarizes current knowledge on the role in antifungal drug resistance, mode of action and phylogenetic relations of DHA transporters, from the model yeast S. cerevisiae to pathogenic yeasts and filamentous fungi. Through the compilation of the predicted DHA transporters in the medically relevant Candida albicans, C. glabrata, C. parapsilosis, C. lusitaniae, C. tropicalis, C. guilliermondii, Cryptococcus neoformans, and Aspergillus fumigatus species, the fact that only 5% of the DHA transporters from these organisms have been characterized so far is evidenced. The role of these transporters in antifungal drug resistance and in pathogen-host interaction is described and their clinical relevance discussed. Given the knowledge gathered for these few DHA transporters, the need to carry out a systematic characterization of the DHA multidrug efflux pumps in fungal pathogens, with emphasis on their clinical relevance, is highlighted. Frontiers Media S.A. 2014-05-28 /pmc/articles/PMC4035561/ /pubmed/24904431 http://dx.doi.org/10.3389/fphys.2014.00197 Text en Copyright © 2014 Costa, Dias, Sá-Correia and Teixeira. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Costa, Catarina
Dias, Paulo J.
Sá-Correia, Isabel
Teixeira, Miguel C.
MFS multidrug transporters in pathogenic fungi: do they have real clinical impact?
title MFS multidrug transporters in pathogenic fungi: do they have real clinical impact?
title_full MFS multidrug transporters in pathogenic fungi: do they have real clinical impact?
title_fullStr MFS multidrug transporters in pathogenic fungi: do they have real clinical impact?
title_full_unstemmed MFS multidrug transporters in pathogenic fungi: do they have real clinical impact?
title_short MFS multidrug transporters in pathogenic fungi: do they have real clinical impact?
title_sort mfs multidrug transporters in pathogenic fungi: do they have real clinical impact?
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035561/
https://www.ncbi.nlm.nih.gov/pubmed/24904431
http://dx.doi.org/10.3389/fphys.2014.00197
work_keys_str_mv AT costacatarina mfsmultidrugtransportersinpathogenicfungidotheyhaverealclinicalimpact
AT diaspauloj mfsmultidrugtransportersinpathogenicfungidotheyhaverealclinicalimpact
AT sacorreiaisabel mfsmultidrugtransportersinpathogenicfungidotheyhaverealclinicalimpact
AT teixeiramiguelc mfsmultidrugtransportersinpathogenicfungidotheyhaverealclinicalimpact